Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451035 | 1.00 | KMT2A (0.39) | KMT2AMEN1CACNA1BHSD11B1CYP2D6 | |
| SCHEMBL30451556 | 0.94 | HSD11B1 (0.39) | KMT2AMEN1CACNA1BHSD11B1CYP2D6 | |
| SCHEMBL22284395 | 0.94 | HSD11B1 (0.39) | KMT2AMEN1CACNA1BHSD11B1CYP2D6 | |
| SCHEMBL22284397 | 0.94 | HSD11B1 (0.39) | KMT2AMEN1CACNA1BHSD11B1CYP2D6 | |
| SCHEMBL22284406 | 0.91 | NR1H2 (0.45) | CACNA1BHSD11B1CYP2D6GPR119NR1H2 | |
| SCHEMBL30451645 | 0.91 | NR1H2 (0.45) | CACNA1BHSD11B1CYP2D6GPR119NR1H2 | |
| SCHEMBL22310516 | 0.91 | NR1H2 (0.45) | CACNA1BHSD11B1CYP2D6GPR119NR1H2 | |
| SCHEMBL22284408 | 0.91 | NR1H2 (0.45) | CACNA1BHSD11B1CYP2D6GPR119NR1H2 | |
| SCHEMBL22311355 | 0.86 | NR1H2 (0.41) | KMT2AMEN1CACNA1BCYP2D6GPR119 | |
| SCHEMBL22311114 | 0.86 | NR1H2 (0.41) | KMT2AMEN1CACNA1BCYP2D6GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | KMT2A 1588/4885MEN1 4463/4885CACNA1B 3397/4885 |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | KMT2A 1588/4885MEN1 4463/4885CACNA1B 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.